We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Detects Alzheimer's with 97% Accuracy 10 Years Before Symptoms Emerge

By LabMedica International staff writers
Posted on 10 Mar 2023

The onset of Alzheimer's disease (AD) pathology can occur a decade or more before the appearance of hallmark symptoms. More...

Now, a newly-developed blood test has the ability to detect AD-associated pathology up to 10 years before the onset of symptoms with an impressive 97% accuracy rate. The test has enormous potential to create a positive impact on effective treatments for AD. The test is minimally invasive, cost-effective, capable of diagnosing or predicting clinical decline in individuals without symptoms, and can track a patient's progress over treatment. As a result, it can effectively be used in clinical trials, as well as in frontline and community primary care settings, particularly in rural and economically disadvantaged areas.

In a recent study, researchers from Rowan University (Glassboro, NJ, USA) and Durin Technologies (Mullica Hill, NJ, USA) analyzed 328 blood samples to investigate if a test that monitors a limited number of a patient's autoantibodies can detect AD-related pathology in the pre-symptomatic, prodromal (i.e., mild cognitive impairment), and mild-moderate stages. The study revealed that the test, utilizing only eight autoantibody biomarkers, could accurately identify the presence of AD pathology throughout the progression of the disease, including in patients who had been previously deemed to have no symptoms of the disease. The application of autoantibodies as blood-based biomarkers is particularly encouraging, according to the researchers as it enables the development of a universal early detection platform for multiple diseases.

"Alzheimer's disease pathology begins a decade or more before the emergence of hallmark symptoms," explained Dr. Robert Nagele, the founder and chief scientific officer at Durin Technologies, Inc., and a professor of Geriatrics and Gerontology at Rowan-Virtua SOM. "An accurate, non-invasive blood test for early detection and monitoring of AD could bend the curve of clinical outcomes through earlier participation in clinical trials and monitoring of AD progression of patients under treatment."

"Our test correctly identified nearly 97% of participants who were diagnosed as cognitively normal at the time their samples were taken, but who progressed, within an average of 48 months, to either the mild cognitive impairment stage or more advanced Alzheimer's disease," said Dr. Cassandra DeMarshall, the study's lead investigator and Durin's director of research. "To our knowledge, this is the first blood test to accurately detect Alzheimer's-related pathology several years before either clinical symptoms or more expensive and invasive tests can identify the disease."

Related Links:
Rowan University
Durin Technologies


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.